LOS ANGELES, Sept 28 (Reuters) - Delcath Systems Inc (DCTH.O) expects to finish an application for U.S. review of its cancer drug delivery system in the fourth quarter, which would put it on track for approval by mid-2011, according to the company’s chief financial officer.
